股票代码：600866 股票简称：星湖科技 公告编号：临 2023-029 广东肇庆星湖生物科技股份有限公司 监事会会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、监事会会议召开情况 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）第十届 监事会第十九次会议于 2023 年 8 月 25 日召开，会议应参会监事 3 人， 实际参会监事 3 人，其中监事张磊以通讯方式参加本次会议。会议由 监事会主席吴柱鑫先生主持。会议的召集、召开符合有关法律、法规 和本公司章程的规定。 二、监事会会议审议情况 会议审议并一致表决通过以下议案： 同意提名张磊女士、许荣丹女士为公司新一届监事会非职工代表 监事候选人。监事任期 3 年，自股东大会选举通过之日起计算。本议 案须提交公司股东大会审议，股东大会将对上述被提名人选以累积投 票制进行表决（候选人简历见附件）。 （一）《关于 2023 年半年度报告（全文及摘要）的议案》 公司监事会关于 2023 年半年度报告的审核意见： 1.公司 2023 年半年度报告的编制符合法律、法 ...

2023 年第一季度报告 证券代码：600866 证券简称：星湖科技 广东肇庆星湖生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | | 本报告期比上 年同期增减变 动幅度(%) | | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | | 营业收入 | 4,163,243,647.49 | 277,656,519.86 | 4,170,645,177.54 | -0.18 | | 归属于上市公司股 东的净 ...

重要内容提示： 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 28 日发布公司 2022 年度报告，为便于广大投资者更全 面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 25 日 上午 11:00-12:00 举行 2022 年度业绩说明会， 就投资者关心的问题进行交流。 证券代码：600866 证券简称：星湖科技 公告编号：临 2023-019 广东肇庆星湖生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 会议召开时间：2023 年 04 月 25 日(星期二) 上午 11:00- 12:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 ...

Financial Performance - In 2022, the company's operating revenue reached RMB 17.49 billion, an increase of 329.51% compared to RMB 4.07 billion in 2021[21]. - The net profit attributable to shareholders was RMB 608.33 million, up 299.85% from RMB 152.14 million in the previous year[21]. - The net cash flow from operating activities was RMB 1.66 billion, representing an increase of 888.42% compared to RMB 168.20 million in 2021[21]. - Basic earnings per share increased by 171.58% to CNY 0.5122 in 2022 from CNY 0.1886 in 2021[23]. - The weighted average return on equity rose by 6.26 percentage points to 13.46% in 2022, compared to 7.20% in 2021[23]. - The company achieved a sales revenue of 17.486 billion yuan in 2022, representing a year-on-year growth of 329.51%[32]. - The net profit attributable to shareholders reached 608 million yuan, with a year-on-year increase of 299.85%[32]. - The total revenue for the year 2022 was 18,800 million, with a net profit of 1,095.17 million[128]. Assets and Liabilities - The total assets at the end of 2022 amounted to RMB 15.99 billion, a slight increase of 0.86% from RMB 15.86 billion at the end of 2021[22]. - The total assets as of December 31, 2022, amounted to 15.998 billion yuan, with total liabilities of 9.069 billion yuan, resulting in a debt-to-asset ratio of 56.69%[32]. - The company reported cash and cash equivalents of CNY 205,263,422.55, which includes various guarantees and deposits[88]. - The total fixed assets were valued at CNY 4,404,583,006.49, primarily secured by loans[88]. Mergers and Acquisitions - The company completed the acquisition of 99.22% of Yipin Biological on November 22, 2022, significantly impacting its financial performance[57]. - The acquisition of 99.22% of Yipin Biological significantly enhanced the company's asset scale and profitability, facilitating a leap in development[33]. - The company completed the acquisition of 99.22% of Yipin Biotechnology, making it a subsidiary[100]. - The company approved a proposal for issuing shares and cash to acquire assets and raise matching funds, indicating a significant asset restructuring plan[138]. Market and Industry Trends - The global demand for monosodium glutamate is projected to grow at an annual rate of approximately 1.4% over the next five years, indicating a stable market for food additives[40]. - The feed additive industry is benefiting from national policies that promote the healthy development of large enterprises, with significant advancements in biotechnology and agricultural modernization[38]. - The company aims to become a leader in the Chinese bio-fermentation industry by focusing on three main sectors: food and feed additives, and pharmaceuticals, while enhancing its industrial layout[115]. Risks and Challenges - The management has outlined potential risks and unfavorable factors that may affect future operations in the report[7]. - The company faces operational management risks due to increased responsibilities after the acquisition of Yipin Bio, which may complicate its management structure[117]. - Market competition risks are heightened as major enterprises actively pursue vertical and horizontal expansions, potentially leading to a decrease in market share and profitability if the company fails to adapt[117]. - Financial risks are present due to a relatively high debt ratio post-restructuring, which may limit the company's ability to finance further production expansion[118]. Research and Development - The company has established a research and development strategy that supports sustainable high-quality development, with significant reductions in product costs[34]. - Research and development expenses reached RMB 106,065,780.88, also reflecting the consolidation of Yipin Biological[55]. - The company is investing heavily in R&D for new technologies, with an allocation of 5.83 million towards innovative projects[128]. Environmental Responsibility - The company has established a complete set of environmental protection facilities, ensuring a 100% operational rate[171]. - The company achieved stable pollutant discharge levels in 2022, meeting industry and national standards[164]. - The company has invested in various environmental technology upgrades, including wastewater and waste gas treatment projects, to enhance pollution control efforts[184]. Corporate Governance - The company has a total of 12 board members and supervisors, with 5 being independent directors[127]. - The board of directors held 9 meetings during the year, with all members attending in person[142]. - The independent directors participated fully in board meetings, with no absences recorded[141]. Social Responsibility - The company has committed to social responsibility initiatives, contributing a total of 3.4742 million yuan to various charitable projects, including education and poverty alleviation[188]. - The company has established rural economic cooperatives to strengthen collective economic growth in key villages[192]. - The company has invested a total of 30 million yuan in rural revitalization work funding in 2022, which includes 7 million yuan for streetlight projects and 17 million yuan for the first phase of the collective economic project in Jiyi Village[193].

Financial Performance - The company's operating revenue for Q3 2022 was ¥352,003,207.03, representing a year-on-year increase of 34.43% compared to ¥261,854,216.31 in the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 reached ¥38,810,913.33, a significant increase from ¥-7,298,336.71 in the same period last year, marking an increase of 104.50% year-to-date[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,388,714.13, up 105.92% from ¥-9,771,788.03 in the same period last year[8]. - Total operating revenue for the first three quarters of 2022 reached ¥982,756,979.74, an increase of 14.3% compared to ¥859,617,648.57 in the same period of 2021[33]. - Net profit for the first three quarters of 2022 was ¥117,248,561.32, compared to ¥57,335,596.98 in 2021, indicating a significant increase of 104.5%[35]. - Basic earnings per share for Q3 2022 were ¥0.0525, up from ¥0.0048 in the same period last year, reflecting a year-to-date increase of 104.51%[8]. - The company reported a basic earnings per share of ¥0.1587, up from ¥0.0776 in the previous year, marking a 104.0% increase[35]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥132,178,961.91, a substantial increase of 187.36% compared to ¥45,998,317.29 in the same period last year[8]. - Operating cash inflow for the first three quarters of 2022 reached CNY 905,124,796, an increase of 24.3% compared to CNY 728,339,940 in the same period of 2021[39]. - Cash outflow for purchasing goods and services was CNY 519,894,473.11, up from CNY 393,603,287.43, reflecting a 32.1% increase year-over-year[39]. - The ending balance of cash and cash equivalents increased to CNY 280,999,453.43 from CNY 219,109,783.36, representing a growth of 28.2%[42]. - The company's cash and cash equivalents stood at 280,999,453.43 RMB, compared to 231,033,037.97 RMB at the end of 2021, reflecting a growth of approximately 21.6%[26]. - Total assets at the end of the reporting period were ¥2,505,830,701.27, representing a 2.56% increase from ¥2,473,349,312.72 at the end of the previous year[8]. Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 44,367, with the largest shareholder, Guangdong Guangxin Holdings Group Co., Ltd., holding 149,422,420 shares, representing 20.22% of the total[19]. - Shareholders' equity attributable to the parent company increased to ¥1,863,167,856.87, a rise of 6.73% from ¥1,775,607,578.86 at the end of the previous year[8]. - The total equity attributable to shareholders reached ¥1,863,167,856.87, compared to ¥1,745,617,972.10, an increase of 6.7%[33]. Market and Operational Insights - The increase in revenue was primarily driven by strong market demand for the company's main products, nucleotides and certain raw materials, leading to a rise in both sales volume and price[15]. - The company reported a significant improvement in gross profit due to favorable market conditions, resulting in a strong growth in operating performance[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[38]. Liabilities and Expenses - Total liabilities amounted to ¥642,662,844.40, a decrease from ¥697,741,733.86, indicating a reduction of 7.9%[33]. - Non-current liabilities totaled ¥296,726,393.74, up from ¥261,428,086.72, reflecting a growth of 13.5%[33]. - Research and development expenses increased to ¥54,441,204.85 from ¥46,032,373.88, representing a growth of 18.5%[33]. Acquisition Plans - The company is in the process of acquiring 99.22% of Ningxia Yipin Biotechnology Co., Ltd., with the transaction pending approval from the China Securities Regulatory Commission[22]. - The company plans to issue shares to raise funds to support the acquisition, pending regulatory approval, which introduces uncertainty regarding the timing and success of the transaction[22].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 630,753,772.71, representing a 5.52% increase compared to RMB 597,763,432.26 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was RMB 78,437,647.99, a 21.36% increase from RMB 64,633,933.69 in the previous year[20]. - The net cash flow from operating activities was RMB 34,479,030.27, a significant recovery from a negative cash flow of RMB -11,942,434.23 in the same period last year[20]. - Basic earnings per share for the first half of 2022 were RMB 0.1061, up 21.26% from RMB 0.0875 in the same period last year[20]. - The weighted average return on net assets increased to 4.39%, up 0.59 percentage points from 3.80% in the previous year[20]. - The company reported a net profit after deducting non-recurring gains and losses of RMB 72,565,857.53, which is a 21.41% increase from RMB 59,769,715.12 in the same period last year[20]. - The total profit for the first half of 2022 was RMB 80,002,273.37, an increase from RMB 68,370,619.60 in the first half of 2021[132]. - Tax expenses decreased to RMB 1,564,625.38 from RMB 3,736,685.91, contributing to higher net profit[132]. Revenue Breakdown - In the first half of 2022, the company's sales revenue from food additives reached 442 million RMB, representing a year-on-year increase of 21.49%, accounting for 71.58% of total operating income[28]. - The sales revenue from chemical raw materials and intermediates was 176 million RMB, showing a year-on-year decrease of 22.12%, which accounted for 28.42% of total operating income[28]. - The company achieved a sales revenue of 631 million RMB, an increase of 32.99 million RMB, representing a growth of 5.52% year-on-year[32]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 2,438,475,427.42, showing a slight decrease of 0.20% from RMB 2,443,359,705.96 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased to RMB 1,824,361,971.23, reflecting a growth of 4.51% from RMB 1,745,617,972.10 at the end of the previous year[20]. - Current liabilities totaled CNY 436,313,647.14, an increase of 25.3% from CNY 347,935,129.98 in the previous period[120]. - Non-current liabilities amounted to CNY 261,428,086.72, showing a slight increase of 1.4% from CNY 266,178,326.21[120]. - Total liabilities reached CNY 697,741,733.86, reflecting a decrease of 12.0% compared to CNY 614,113,456.19[120]. Research and Development - The company is focusing on the development of new amino acid raw materials, aiming for breakthroughs in product innovation and optimizing existing production processes[35]. - Research and development expenses increased to RMB 38,529,581.09, up from RMB 31,647,072.30, indicating a focus on innovation[129]. - The company aims to enhance its R&D capabilities and accelerate the application of new products and technologies through industry-academia collaboration[52]. Environmental Commitment - The company is committed to enhancing safety and environmental standards, implementing various safety measures and promoting green development initiatives[35]. - The company has established a comprehensive environmental protection system with a 100% operational rate for pollution control facilities[66]. - The company actively implemented clean production measures, achieving stable operation of pollution control facilities across all subsidiaries[66]. - The company has developed emergency response plans for environmental incidents, which have been filed with local environmental authorities[70]. - The company’s emissions of CODcr were controlled at 60.61 tons, well below the allowed total of 226.24 tons per year[65]. Strategic Initiatives - The company has initiated a major asset restructuring plan, aiming to acquire 99.22% of Yipin Biological's shares, which could significantly impact its financial structure and profitability[36]. - The company is actively pursuing market expansion and has strengthened its marketing network, establishing long-term strategic partnerships with major domestic and international enterprises[31]. - The company plans to continue its market expansion and strategic acquisitions in the future[106]. Legal and Compliance Issues - The company is currently involved in a patent lawsuit with CJ First Sugar Co., which claims infringement on its I+G and IMP products, with potential compensation claims of RMB 20 million[52]. - The company has not disclosed any updates on employee stock ownership plans or other incentive measures[62]. - The company has not provided guarantees to shareholders, actual controllers, or related parties during the reporting period[102]. Financial Management - The company has established a financial shared service center to enhance financial management capabilities across production, sales, and inventory[52]. - The company has applied to the China Securities Regulatory Commission to resume the review of the asset acquisition and fundraising matters[106]. - The total amount of guarantees provided by the company, including those to subsidiaries, was 38,398.96 million RMB, accounting for 21.05% of the company's net assets[102].

Financial Performance - The company's operating revenue for Q1 2022 was ¥277,656,519.86, a decrease of 8.68% compared to ¥304,035,337.29 in the same period last year[6] - Net profit attributable to shareholders was ¥22,903,798.56, down 33.82% from ¥34,610,819.02 year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,375,103.83, a decline of 38.28% compared to ¥31,390,929.21 in the previous year[6] - Basic and diluted earnings per share were both ¥0.0310, representing a decrease of 33.76% from ¥0.0468 in the same period last year[8] - The weighted average return on equity was 1.30%, down 0.75 percentage points from 2.05% year-on-year[8] - Total operating revenue for Q1 2022 was ¥277,656,519.86, a decrease of 8.7% compared to ¥304,035,337.29 in Q1 2021[30] - Net profit for Q1 2022 was ¥22,903,798.56, a decline of 33.9% compared to ¥34,610,819.02 in Q1 2021[31] - Basic earnings per share for Q1 2022 were ¥0.0310, down from ¥0.0468 in Q1 2021[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,401,337,577.24, a decrease of 1.72% from ¥2,473,349,312.72 at the end of the previous year[8] - Total liabilities amounted to ¥632,885,790.85, down from ¥697,741,733.86 in the previous period[27] - Non-current liabilities totaled ¥281,791,222.56, an increase from ¥261,428,086.72 in the previous period[27] - The company's retained earnings showed a slight improvement, with a deficit of ¥225,308,221.30 compared to a deficit of ¥248,212,019.87 in the previous period[27] Cash Flow - The net cash flow from operating activities was negative at -¥7,392,672.67, compared to ¥14,120,009.43 in the same period last year[6] - In Q1 2022, the cash inflow from operating activities was CNY 292,535,654.61, an increase of 22.5% compared to CNY 238,805,563.24 in Q1 2021[36] - The cash outflow from operating activities totaled CNY 299,928,327.28, up from CNY 244,611,026.63 in the same period last year, representing a 22.6% increase[36] - The net cash flow from operating activities was negative at CNY -7,392,672.67, worsening from CNY -5,805,463.39 in Q1 2021[36] - Cash inflow from investment activities was CNY 1,209,125.44, significantly higher than CNY 100,896.60 in Q1 2021[36] - Cash outflow from investment activities decreased to CNY 54,171,559.32 from CNY 67,005,826.17 year-over-year, a reduction of 19.1%[36] - The net cash flow from investment activities was CNY -52,962,433.88, an improvement from CNY -66,904,929.57 in the previous year[36] - Cash inflow from financing activities was CNY 81,402,598.12, down from CNY 109,910,430.35 in Q1 2021, a decline of 26.0%[36] - Cash outflow from financing activities decreased to CNY 38,506,777.58 from CNY 40,351,985.53, a reduction of 4.6%[36] - The net cash flow from financing activities was CNY 42,895,820.54, down from CNY 69,558,444.82 in the same quarter last year[36] - The ending cash and cash equivalents balance was CNY 213,573,751.96, a decrease from CNY 229,398,288.27 at the end of Q1 2021[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 58,896[17] - The largest shareholder, Guangdong Guangxin Holdings Group Co., Ltd., holds 149,422,420 shares, representing 20.22% of total shares[17] - The company has not disclosed any related party relationships among the top shareholders[17] - The company has not reported any financing or securities lending activities involving the top ten shareholders[17] Operational Challenges - The decrease in gross profit was primarily due to the impact of pandemic control measures and the Russia-Ukraine conflict, which affected the delivery of major products in certain domestic and international markets[14] Research and Development - Research and development expenses increased to ¥18,280,410.78 in Q1 2022, up from ¥15,861,549.18 in Q1 2021, reflecting a growth of 15.2%[30] Asset Restructuring - The company is undergoing a major asset restructuring, with the audit and evaluation of the involved assets not yet completed[20]

Financial Performance - The company reported a negative cumulative profit available for distribution to shareholders for the year 2021, thus no profit distribution or capital reserve transfer to share capital will be made[4]. - The company's operating revenue for 2021 was ¥1,235,046,858.04, representing a 10.64% increase compared to ¥1,116,277,268.22 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥106,469,880.70, a decrease of 28.40% from ¥148,710,264.03 in 2020[19]. - The net cash flow from operating activities decreased by 22.94% to ¥192,629,097.87 in 2021 from ¥249,985,729.49 in 2020[19]. - The total assets at the end of 2021 were ¥2,473,349,312.72, a 2.12% increase from ¥2,421,969,298.10 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥0.1441, down 28.38% from ¥0.2012 in 2020[19]. - The weighted average return on equity for 2021 was 6.18%, a decrease of 3.15 percentage points from 9.33% in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥96,787,505.70, down 23.49% from ¥126,499,195.65 in 2020[19]. - The company reported a net profit of ¥34,610,819.02 in Q1 2021, with a decline in Q3 to ¥3,571,198.48[22]. Revenue Breakdown - The sales revenue from food additives reached 768 million yuan, an increase of 10.33% year-on-year, accounting for 62.94% of total revenue[31]. - The sales revenue from chemical raw materials and intermediates was 453 million yuan, with a year-on-year increase of 10.46%, making up 37.06% of total revenue[34]. - The company achieved a revenue of 1.235 billion RMB, representing a year-on-year growth of 10.64%[40]. - The company's revenue from the food and feed additives industry increased by 10.33% year-on-year, driven by a 16.32% increase in nucleotide product sales[46]. - Revenue from the biochemical raw materials and pharmaceutical intermediates industry rose by 10.46% year-on-year, with all product categories exceeding 10% growth[46]. Cost and Expenses - The gross profit margin for food additives was 24.97%, down by 7.45 percentage points year-on-year[41]. - The company faced a significant increase in operating costs, with total operating costs rising by 24.29% to 928 million RMB[41]. - Research and development expenses increased by 17.38% to 68.88 million RMB, reflecting the company's commitment to product development[41]. - The total cost of goods sold increased by 42.11% year-on-year, with raw materials accounting for 70.32% of total costs[50]. Investments and Acquisitions - The company invested CNY 6.11 billion in the Zhaodong biological fermentation industrial park project, which has been completed and is now in production[80]. - The company acquired a 3.3333% stake in Guangdong Guangxin Innovation Research Institute for CNY 11.18 million[79]. - The company completed the acquisition of Jiuling Pharmaceutical in 2019, and if its future performance does not meet expectations, there is a risk of goodwill impairment[95]. - A strategic acquisition of a local competitor was completed, valued at 500 million yuan, aimed at enhancing market capabilities[113]. Risk Management - The company faces risks related to raw material price fluctuations, particularly corn starch, which significantly impacts production costs[92]. - The company has established a strict safety production management system to mitigate risks associated with production operations and environmental compliance[92]. - The company faces risks related to foreign exchange fluctuations, particularly as its export products are primarily priced and settled in USD, which could impact operating performance if the RMB appreciates significantly against the USD[95]. - The company is involved in a patent lawsuit regarding its I+G and IMP products, with a potential liability of RMB 20 million if it loses the case, which could adversely affect its financial results[95]. Corporate Governance - The audit report for the company was issued by Xinyong Zhonghe Accounting Firm with a standard unqualified opinion[4]. - The company has not encountered any non-operating fund occupation by controlling shareholders or related parties[4]. - The company has established a clear cash dividend policy and strictly executed it during the reporting period without any adjustments[142]. - The company has conducted a self-inspection of corporate governance, identifying issues related to historical losses and compliance with shareholder meeting requirements[149]. Environmental Responsibility - The company has maintained stable pollutant discharge levels in 2021, meeting industry and national standards for emissions[151]. - The company has established a complete environmental protection facility with a 100% operational rate, ensuring compliance with environmental regulations[155]. - The company is committed to sustainable development, integrating economic growth with environmental protection initiatives[155]. - The company has engaged in strategic partnerships with high-level research institutions to innovate environmental protection technologies, with projects reaching internationally leading standards[163]. Employee and Talent Management - The company has a total of 2,608 employees, with 1,620 in the parent company and 988 in major subsidiaries[137]. - The company has established a competitive and incentive-based compensation policy, ensuring that key talent compensation levels are competitive[138]. - The company has implemented a comprehensive occupational health and safety management system, emphasizing employee safety and health in the workplace[167]. - The company has developed targeted training plans for frontline production employees to improve their skills and ensure safety and quality in production[141]. Future Outlook and Strategy - The company plans to focus on significant capital needs for technological transformation projects and operational expenditures in 2022[4]. - The company aims to enhance its health food segment and integrate its pharmaceutical supply chain through mergers and acquisitions and technological innovation[90]. - The company plans to implement a digital transformation strategy to drive industrial upgrades and expand its business layout in 2022[91]. - The company provided a performance guidance for 2022, expecting a revenue growth of 20% compared to 2021[123].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600866 证券简称：星湖科技 广东肇庆星湖生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------------------|----------------|--------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥581.05 million, a decrease of 0.71% compared to the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥76.03 million, down 9.11% year-on-year[21]. - Basic earnings per share for the first half of 2021 were ¥0.1029, a decrease of 9.10% compared to the same period last year[22]. - The company's gross profit margin was impacted by a 10.28% increase in operating costs, driven by a more than 40% rise in the prices of key raw materials like corn starch[33]. - The company reported a significant reduction in selling expenses by 67.55% to CNY 3.98 million, mainly due to decreased employee compensation and promotional costs[32]. - The total profit for the first half of 2021 was CNY 79,763,270.68, a decrease of 8.0% compared to CNY 87,531,531.48 in the same period of 2020[145]. - The net profit for the first half of 2021 was CNY 76,026,584.77, a decrease of 9.2% compared to CNY 83,646,752.37 in the first half of 2020[145]. Cash Flow and Financial Position - The net cash flow from operating activities significantly decreased by 93.74%, amounting to approximately ¥6.02 million[21]. - The net cash flow from financing activities increased by 103.34% to CNY 81.25 million, attributed to increased bank loans for project financing[33]. - The company’s cash and cash equivalents decreased to CNY 215,867,228.02 from CNY 232,550,236.41, a decline of approximately 7.2%[131]. - The cash flow from operating activities generated a net amount of ¥6.02 million, a decrease of 93.7% compared to ¥96.16 million in the same period last year[153]. - The total assets at the end of the reporting period were approximately ¥2.55 billion, an increase of 5.09% compared to the end of the previous year[21]. - Total current assets as of June 30, 2021, amounted to CNY 848,351,167.65, an increase from CNY 726,024,447.79 as of December 31, 2020, reflecting a growth of approximately 16.8%[131]. Investments and Subsidiaries - The health industry subsidiary, established with a registered capital of 50 million RMB, has total assets of 46.79 million RMB but reported a net loss of 699,000 RMB in the first half of 2021[46]. - Jiu Ling Pharmaceutical, fully owned by the company, achieved a revenue of 80.07 million RMB in the first half of 2021, contributing 13.78% to the company's total revenue, with a net profit of 1.76 million RMB, accounting for 23.12% of the company's net profit[46]. - The company has invested a total of 5.81 billion RMB in the first phase of the Zhaodong Bio-fermentation Industrial Park, with a planned investment not exceeding 6.8 billion RMB, and the project is now in trial production[44]. - The company has established a new subsidiary focused on health products, indicating a strategic expansion into the health sector[44]. Environmental Compliance - The company maintains a 100% operational rate for its environmental protection facilities, ensuring compliance with national standards[64]. - The company’s biological engineering base and pharmaceutical plants are classified as key pollution sources, with emissions consistently meeting industry and national standards[60]. - The company has established emergency response plans for environmental incidents, which have been filed with local environmental authorities[66]. - During the reporting period, the company faced administrative penalties totaling CNY 96.49 million due to environmental issues, including CNY 26.37 million for improper wastewater disposal and CNY 58 million for premature production without completed environmental facilities[71]. Strategic Decisions and Changes - The company did not propose any profit distribution plan or capital reserve transfer to share capital during the reporting period[6]. - The company has terminated the investment contract for the green health industry park, reflecting a strategic decision to withdraw from that project[44]. - Two directors, Chen Zhipeng and Xu Rongdan, resigned due to work adjustments, while Wang Li and Pang Bixia were elected as new directors[55]. - The company has initiated a lawsuit regarding patent infringement, which could result in significant financial implications if the court rules against it, with potential damages amounting to 20 million RMB[50]. Shareholder Information - The total number of shares before the change was 739,019,166, with 97.74% being unrestricted shares[113]. - The company issued 16,665,955 new shares during the reporting period, resulting in a total of 739,019,166 shares after the change[113]. - The number of shareholders reached 47,613 by the end of the reporting period[119]. - Guangdong Province Guangxin Holdings Group Co., Ltd. held 134,642,420 shares, representing 18.22% of total shares[119]. Research and Development - Research and development expenses increased by 51.91% to CNY 31.65 million, reflecting the company's commitment to product development[32]. - Research and development expenses increased to ¥15.40 million, up 37.8% from ¥11.21 million in the previous year, indicating a focus on innovation[149]. Risk Management - The company has detailed potential risks in the report, which investors should be aware of[7]. - The company faces risks related to production costs and price fluctuations, particularly due to reliance on corn starch as a primary raw material[50].